Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

MLA

Gianni L, et al. “Treatment with Trastuzumab for 1 Year after Adjuvant Chemotherapy in Patients with HER2-Positive Early Breast Cancer: A 4-Year Follow-up of a Randomised Controlled Trial.” Lancet Oncology, vol. 12, no. 3, Mar. 2011, pp. 236–44. EBSCOhost, https://doi.org/10.1016/s1470-2045(11)70033-x.

APA

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, & Shen Z. (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology, 12(3), 236–244. https://doi.org/10.1016/s1470-2045(11)70033-x

Chicago

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, et al. 2011. “Treatment with Trastuzumab for 1 Year after Adjuvant Chemotherapy in Patients with HER2-Positive Early Breast Cancer: A 4-Year Follow-up of a Randomised Controlled Trial.” Lancet Oncology 12 (3): 236–44. doi:10.1016/s1470-2045(11)70033-x.